SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.